S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:BXRX

Baudax Bio Stock Forecast, Price & News

$1.22
+0.02 (+1.67 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.05
Now: $1.22
$1.22
50-Day Range
$1.20
MA: $1.53
$1.95
52-Week Range
$0.97
Now: $1.22
$6.97
Volume3.48 million shs
Average Volume7.57 million shs
Market Capitalization$85.57 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Baudax Bio logo

Headlines

Baudax Inch up on Q4 Results
February 16, 2021 |  baystreet.ca
Baudax Bio: Q4 Earnings Insights
February 16, 2021 |  benzinga.com
Baudax Bio Reports 2020 Annual Financial Results
February 16, 2021 |  finance.yahoo.com
Baudax Bio plans $17.6M direct stock offering
February 11, 2021 |  bizjournals.com
Is BXRX A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
Malvern's Baudax Bio plans $12 million stock offering
November 23, 2020 |  bizjournals.com
Baudax Bio Reports Third Quarter 2020 Financial Results
November 9, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BXRX
CUSIPN/A
CIKN/A
Phone484-395-2470
Employees24
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$85.57 million
Next Earnings Date5/14/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

655th out of 1,972 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

9th out of 25 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.22
+0.02 (+1.67 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BXRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Baudax Bio (NASDAQ:BXRX) Frequently Asked Questions

Is Baudax Bio a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baudax Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Baudax Bio stock.
View analyst ratings for Baudax Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Baudax Bio?

Wall Street analysts have given Baudax Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Baudax Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Baudax Bio?

Baudax Bio saw a decline in short interest during the month of January. As of January 29th, there was short interest totaling 3,030,000 shares, a decline of 27.2% from the January 14th total of 4,160,000 shares. Based on an average trading volume of 4,990,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 6.4% of the shares of the company are short sold.
View Baudax Bio's Short Interest
.

When is Baudax Bio's next earnings date?

Baudax Bio is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Baudax Bio
.

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) released its quarterly earnings results on Monday, February, 15th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.52.
View Baudax Bio's earnings history
.

How has Baudax Bio's stock been impacted by Coronavirus?

Baudax Bio's stock was trading at $4.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BXRX shares have decreased by 75.3% and is now trading at $1.22.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BXRX?

2 analysts have issued twelve-month price objectives for Baudax Bio's shares. Their forecasts range from $13.00 to $14.00. On average, they anticipate Baudax Bio's stock price to reach $13.50 in the next year. This suggests a possible upside of 1,006.6% from the stock's current price.
View analysts' price targets for Baudax Bio
or view top-rated stocks among Wall Street analysts.

Who are Baudax Bio's key executives?

Baudax Bio's management team includes the following people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 69, Pay $48.37k)
  • Mr. Ryan D. Lake, CFO & Treasurer (Age 44, Pay $29.44k)
  • Dr. Stewart McCallum, Chief Medical Officer (Age 55)
  • Mr. John Harlow, Chief Commercial Officer (Age 45)
  • Mr. Randall J. Mack, Sr. VP of Devel. (Age 56)
  • Ms. Diane Myers, Sr. VP of Regulatory & Quality (Age 57)
  • Dr. Jyrki Mattila, Exec. VP of Bus. Devel. (Age 66)

Who are some of Baudax Bio's key competitors?

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB).

What is Baudax Bio's stock symbol?

Baudax Bio trades on the NASDAQ under the ticker symbol "BXRX."

Who are Baudax Bio's major shareholders?

Baudax Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.99%), Renaissance Technologies LLC (0.99%), GSA Capital Partners LLP (0.52%), Corsair Capital Management L.P. (0.21%), Alyeska Investment Group L.P. (0.12%) and Alyeska Investment Group L.P. (0.19%).
View institutional ownership trends for Baudax Bio
.

Which major investors are selling Baudax Bio stock?

BXRX stock was sold by a variety of institutional investors in the last quarter, including Corsair Capital Management L.P..
View insider buying and selling activity for Baudax Bio
or view top insider-selling stocks.

Which major investors are buying Baudax Bio stock?

BXRX stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Renaissance Technologies LLC, GSA Capital Partners LLP, Alyeska Investment Group L.P., and Alyeska Investment Group L.P..
View insider buying and selling activity for Baudax Bio
or or view top insider-buying stocks.

How do I buy shares of Baudax Bio?

Shares of BXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Baudax Bio's stock price today?

One share of BXRX stock can currently be purchased for approximately $1.22.

How much money does Baudax Bio make?

Baudax Bio has a market capitalization of $85.57 million. The company earns $-32,560,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.

How many employees does Baudax Bio have?

Baudax Bio employs 24 workers across the globe.

What is Baudax Bio's official website?

The official website for Baudax Bio is www.baudaxbio.com.

Where are Baudax Bio's headquarters?

Baudax Bio is headquartered at 490 LAPP ROAD, MALVERN PA, 19355.

How can I contact Baudax Bio?

Baudax Bio's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The company can be reached via phone at 484-395-2470 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.